

Pediatric pharmacology

Understanding ADMET to improve drug design for children

AN INTERACTIVE WEBINAR POWERED BY NEXTLEVEL PHARMA

Event overview

This will be a half day webinar for clinical pharmacologists, scientists and pediatricians to discuss overcoming the scientific challenges in designing PK/PD studies to aid developing new pediatric medicines.

It is widely known that recent regulatory changes on both sides of the Atlantic have meant a higher priority is placed on developing medicines for children that have undergone rigorous examination. Many previous discussions have taken place on the difficult topic of clinical trials in pediatric populations. However this webinar will not be just another discussion about issues surrounding submitting PIPs, the changes in regulatory requirements or the operational challenges in locating pediatric subjects and informed consent.

NextLevel Pharma's focused and interactive webinar will look to concentrate on the position that pharmacokinetic and pharmacodynamic modelling and simulations have to answer the questions of how children metabolize drugs differently, how to assess optimal drug dosage levels and optimise the design of pediatric studies.

Experienced industry pharmacologists and pediatricians will join us to discuss recent developments and assess how to better understand drug interaction, determine the optimal dosage and report on efficacy in children.

Why participate?

- Understand the need for pk/pk studies: the when, how and why in the eyes of the regulators.
- Learn what roles pk/pd studies have in the development of pediatric drugs and how they can be used more effectively to determine dosages, measure efficacy and demonstrate value to the pediatric world.
- Hear case study presentations from industry leaders on how to adapt methods used from adult to children and gain fresh perspectives from experienced pharmaceutical companies who have successfully integrated pk/pd into pediatric studies for optimal design.
- Discover which approaches are best to predict dosage, utilize existing (adult) data, and understand the interactions between drug and child.

Who will benefit:

Pharmaceutical & Biotechnology Organisations:

Vice- Presidents, Directors, Managers;

Pediatrics, Pre-Clinical and Clinical Pharmacologists, Pharmacokinetics, Pharmacodynamics, Modelling and simulation specialists, Early Drug Development, Clinical development and strategy, Clinical scientists, Medical directors

Academics;

Pediatricians, pharmacologists and scientists involved in the development of new pediatric medicines

Prestigious Speaker Panel

Chairperson:

Roger D. Toothaker, PhD,

Vice President, Pharmacokinetics, Pharmacodynamics, Modeling & Simulation

ICON Development Solutions

Andrew E Mulberg, MD, FAAP, CPI

Portfolio Leader, Internal Medicine, Established Products CNS/IM Late Development

Johnson & Johnson Pharmaceutical Research and Development, USA

Jeffrey S. Barrett, Ph.D., FCP,

Research Associate Professor, Pediatrics Director, Pediatric Pharmacology Research Unit

Laboratory for Applied PK/PD Clinical Pharmacology & Therapeutics Abramson Research Center, The Children's Hospital of Philadelphia

Pravin R Jadhav

Pharmacometrics Team Leader

FDA, USA

Armel Stockis

Senior Director, Global exploratory development

UCB, Belgium

Pieter Guelen, Chairman

Pharmacokinetic Consultancy Services

Netherlands

**Platinum
Event
Partner**



Development Solutions

Media Partners



Pediatric pharmacology

Understanding ADMET to improve drug design for children

AN INTERACTIVE WEBINAR POWERED BY NEXTLEVEL PHARMA

Interactive Webinar Programme

Chairperson: Roger D. Toothaker, PhD,
Vice President, Pharmacokinetics, Pharmacodynamics
Modeling & Simulation
ICON Development Solutions

CET

15.45 Online login

16.00 Chairperson's opening remarks

16.15 **Obstacles and approaches to successful pediatric development**

- Overview of the issues across pediatric age groups.
- Position/Value of PK/PD studies, models and simulations to pediatric drug development.
- What the scientific differences between the pediatric and the adult subject mean to study design.

Andrew E Mulberg, MD, FAAP, CPI
Portfolio Leader, Internal Medicine, Established Products
CNS/IM Late Development,
Johnson & Johnson Pharmaceutical Research and Development, USA

16.55 **Defining the therapeutic window in children via biomarkers and PK/PD modelling when Pediatric**

- Bridging of adult to pediatric experience in NME with similar adult/pediatric indications.
- Need to explore, define, and ultimately defend the pediatric therapeutic window.
- Availability of suitable biomarkers to discriminate doses and regimens.
- Characterizing the time course of doses and exposures that map the concentration-effect or dose-response surface.
- Examples of such approaches.

Jeffrey S. Barrett, Ph.D., FCP
Research Associate Professor, Pediatrics Director, Pediatric Pharmacology Research Unit,
Laboratory for Applied PK/PD Clinical Pharmacology & Therapeutics Abramson Research Center, The Children's Hospital of Philadelphia

17.35 **Correct pediatric dosing through modelling & simulation**

Dr Jadhav will cover the current approach used by scientists at the Office of Clinical Pharmacology in guiding pediatric drug development. Case studies will be presented to demonstrate various methods used and issues encountered in guiding pediatric protocol development. These case studies will demonstrate evaluations of the following aspects of study design:

- Appropriate dose range
- Sample size to design informative PK and efficacy studies
- Use of prior knowledge (adult data or relevant pediatric data)

Pravin R Jadhav, Pharmacometrics Team Leader
FDA, USA

18.05 **Pediatric modelling and simulation for trial design: Case study in anti-epilepsy drugs**

- Physiologically-based pediatric pk predictions (including hepatic and renal maturation factors).
- Pop-pk extrapolations from adult data.

Pediatric pop-pk for dosing recommendations extrapolating clinical response from adults using pop pk/pd.

- Oral to intravenous prediction.
- Optimal trial design.

Armel Stockis, Senior Director Global exploratory development
UCB, Belgium

18.45 **Panel Discussion "Considerations in pediatric study design to enable high operational performance"**

- Audience members will be able to submit questions prior or during the event for discussion.
- Best approaches to pediatric planning / strategy (considerations on company size, drug indication).
- How to utilize existing (adult) data to improve study design.
- Designing pediatric protocol to meet scientific & operational requirements.
- How to incorporate patient and investigator compliance into the protocol.

Pieter Guelen, Chairman
Pharmacokinetic Consultancy Services, Netherlands

19.30 End of webinar

Pediatric pharmacology

Understanding ADMET to improve drug design for children

AN INTERACTIVE WEBINAR POWERED BY NEXTLEVEL PHARMA

How do webinars work?: A six-step guide

1. Register & Payment

Firstly you need to register through your NextLevel Pharma representative by faxing your registration details to +421 232 662 622 or by registering at www.nextlevelpharma.com (5 minutes).

NextLevel Pharma will then execute the payment and then you'll receive the event documentation from us before the event.

2. Account Creation

One week before the webinar you'll receive your account setup information, here you enter in your details and complete a short survey online, so speakers are aware of your level of expertise. (5 minutes).

3. Log-in

On the day of the event you'll need to log in 5-15 minutes before the webinar. This log in will be done online. Then dial the toll free number which you'll be given.

4. Participate and interact

The sessions will then begin all the while you can ask questions via typing them in. Only during the designated question time (at the end of each session) can you verbally ask questions. During the interactive panel discussions you'll need to type your name in the question area, before the moderator will call on you to ask your question. There will be online mini-surveys occasionally during the webinar.

5. Feedback

Once the sessions are over you'll receive a link to the online webinar feedback.

6. View Again

After the event, via the www.nextlevelpharma.com website you'll be able to view the webinar again.



Media Partners



Network and make contact with other participants prior to the webinar.

Submit your questions to be discussed during the event

The screenshot shows a Microsoft Live Meeting 8 Playback window. The browser address bar shows the URL: <https://www323.livemeeting.com/cc/calper/viewFormaHFF/w254tw3d1rcjn731/Engine/Default.htm?https://www323.livemeeting.com/%2Fcc/>. The meeting interface includes a 'Present Speaker' video feed on the left, an 'Upcoming Slides' list, and a main slide area. The current slide is titled 'Upcoming NextLevel Pharma Events: Safety Biomarkers in Drug Development'. The slide content includes the NextLevel Pharma logo, a 'Sponsor logo here' box, and the following text: 'Conference Dates: 14th-15th September, 2009', 'Venue: Falkensteiner Hotel Bratislava, Bratislava, Slovak Republic', 'Knowledge Solutions for Life Sciences', 'Integrating biomarkers into clinical research to predict, diagnose & avoid adverse events', 'Building alliances & networks', and 'pharmaceutical • biotech • diagnostics • academia • solution providers'. The bottom of the window shows a 'Select Views' dropdown and a timer at 00:29:28/00:56:14.

Pediatric pharmacology

WAYS TO REGISTER

OPTION 1: Please complete this form and fax back to: FAX: +421 232 662 622 TEL: +421 232 662 621

OPTION 2: Click here to register online!

Attention: Andrea Valent
andrea.valent@nextlevelpharma.com
Please write in **BLOCK CAPITALS**

Participant Information

PARTICIPANT 1

Name: _____
Job Title: _____
Email: _____

PARTICIPANT 2

Name: _____
Job Title: _____
Email: _____

PARTICIPANT 3

Name: _____
Job Title: _____
Email: _____
Organisation: _____
Address: _____
City: _____ **Country:** _____
Phone: _____
VAT Number: _____

CREDIT CARD PAYMENT: Please debit my card (circle one):

Visa Eurocard/Mastercard Amex Diner's Club

Card Number:

Visa CVC or Eurocard/Mastercard CVV Number

Valid From _____ Expiry Date _____

Card Billing Address: _____

City: _____

Post/Zip Code: _____

Card Holder's Name: _____

Card Holder's Signature - I agree to NextLevel Pharma debiting my card:

I agree to the NextLevel Pharma Terms and Conditions of booking.

Signature: _____

Signatory must be authorised to sign on behalf of contracting organisation. **N.B. A SIGNATURE IS ESSENTIAL BEFORE THIS FORM CAN BE PROCESSED.**

Name _____

Date _____

Pediatric pharmacology webinar

PRICES PER ONLINE GUEST

Early bird single participant package - 10% discount before 17/07/2009	€539.00 each	<input type="checkbox"/>
2 Participants - 30% discount	€838.00 (€419.00 each)	<input type="checkbox"/>
3 Participants - 40% discount	€1077.00 (€359.00 each)	<input type="checkbox"/>
4+ Participants - 50% discount	€1198.00 (€299.50 each)	<input type="checkbox"/>
Single participant package from 20/07/2009	€599.00 each	<input type="checkbox"/>

Please fax this form to +421-232-662-622 **BOOK ONLINE:** at www.nextlevelpharma.com
For high profile sponsorship opportunities, please contact **Luke Rogers** at sponsorship@nextlevelpharma.com

NEXT LEVEL PHARMA Conference Agreement Terms & Conditions of Booking:

- Registration fees include programme materials, food and refreshments.
- Once a completed registration form has been received, full payment is required within 5 working days from receipt of invoice. A receipt will be issued following payment.
- The client recognises that NextLevel Pharma organises high quality events, with strictly limited numbers of participants and incurs expenses as a result. NextLevel Pharma relies on all it's clients to honour the agreement and make the required payment in order to guarantee the conference's success.
- Cancellation & Substitutions: Upon receipt of payment, substitutions of participants can be made at any time before the meeting at no further cost. Once a completed registration form has been received any cancellations will result in a 50% cancellation fee. Cancellations received only 1 month before the conference date cannot be refunded whatsoever. In the result of a cancellation, NextLevel Pharma is willing to provide a credit at full value to the client at any time within 24 hours of the event taking place, upon receiving full payment and written notice of non-attendance. Non-attendance or non-payment does not make this contract void. Payment is always required once the registration form has been received. Payment must be received before the start of the event.
- * For group discounts to apply all participants must register on the same day.

- Whilst all reasonable care and effort has been made, NextLevel Pharma reserves the right to alter the programme content without notice. If, for any reason NextLevel Pharma decides to cancel, postpone or merge this webinar with another webinar, NextLevel Pharma is not responsible for covering any expenses incurred by clients. The webinar fee can be credited to a future event.
- Intellectual Property & Copyright. All NextLevel Pharma materials in relation to this event are exclusively reserved and any unauthorised duplication, publication or distribution is strictly prohibited.
- This agreement shall be governed in accordance with the law of the Slovak Republic and the parties submit to the exclusive jurisdiction of the Slovak Courts. However only NextLevel Pharma is entitled to waive this right and submit to the jurisdiction of the courts in which the client's office is located.
- Client information is kept by NextLevel Pharma and used by NextLevel Pharma to keep clients informed of other related NextLevel Pharma products which may be of interest. If the client does not wish to be contacted further, please tick this box ().
- NextLevel Pharma is thankful of client feedback of our events. In some situations, quotes & testimonials made by clients, may be used by NextLevel Pharma in future marketing literature. If you do not wish to be quoted, please tick this box ().